Mepolizumab (Nucala, GlaxoSmithKline) is indicated for 'add-on maintenance treatment of adult patients with uncontrolled COPD of an eosinophilic phenotype on a combination of an inhaled corticosteroid (ICS), a long acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA)'.
The dosage schedule is available in the summary of product characteristics for mepolizumab.
The list price of mepolizumab is £840.00 for a 100-mg per 1-ml prefilled pen or prefilled syringe (excluding VAT; BNF online, accessed April 2026).
The company has a commercial arrangement. This makes mepolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is available on GlaxoSmithKline's UK webpage.